Innovative Value-Based Price ProgramsBack in the Spotlight
Biopharmaceutical Report I Issue25_December 2021 Value-based plans are emerging as particularly attractive coverage options for therapies...
BioPharmaceutical
Report
- Dec 29, 2021
- 4 min
Upper Middle-Income Countries Left Out by New Merck/Ridgeback COVID-19 Antiviral Licensing Deal
Biopharmaceutical Report II Issue25_December 2021 As Merck (NYSE:MRK) and Ridgeback Biotherapeutics sign on to a licensing deal to expand...
- Sep 29, 2021
- 6 min
Medicare's National Coverage Determination Could Boost Chances of Limited Aduhelm Coverage
Biopharmaceutical Report II Issue24_September 2021 By opening a National Coverage Determination (NCD) on Biogen’s (NASDAQ:BIIB) Aduhelm...
- Sep 29, 2021
- 5 min
Pepaxto's US Uptake to Stall in Multiple Myeloma Until FBA Provides Advice to Address Death Risk
Biopharmaceutical Report I Issue24_September 2021 Blood cancer oncologists are likely to hold back for now on using Oncopeptides’...
- Mar 3, 2021
- 10 min
Innovations Forged in the COVID Crucible Will Reshape Medicine
Steve Usdin, Washington Editor Biopharmaceutical Report III Issue22_March 2021 The fight against COVID-19 is far from finished, but...
- Mar 3, 2021
- 6 min
COVID-19 Long-Hauler Treatments Could Employ Repurposed Trial Endpoints to Prove Aptitude
Biopharmaceutical Report II Issue23_March 2021 COVID-19 long-hauler treatment trials will likely rely on established endpoints and trial...
- Mar 3, 2021
- 7 min
New SARS-CoV-2 Variants Push Back COVID-19 Vaccine Long-Term Durability Questions
Biopharmaceutical Report I Issue23_March 2021 Long-term COVID-19 vaccine durability has become less of an endgame since it has become...
- Nov 4, 2020
- 4 min
Prepping for COVID-19's Next Wave: Is the Glass Half Full or Half Empty?
Biopharmaceutical Report IV Issue22_November 2020 COVID-19 didn’t disappear with summer temperatures, it just shifted locations and...
- Nov 4, 2020
- 4 min
Lessons From Bergamo: Halting the Complement Cascade May Stop COVID-19 in Its Tracks
Biopharmaceutical Report III Issue22_November 2020 Treatments for COVID-19 may be focusing on at the wrong elements of the disease,...
- Nov 4, 2020
- 5 min
Fate and Celyad's CAR Therapies Offer Potential to Amplify Efficacy With Multiple Doses
Biopharmaceutical Report II Issue22_November 2020 Fate Therapeutics’ (NASDAQ:FATE) and Celyad’s (NASDAQ:CYAD) natural killer (NK) cell...
1